NFE2L2 and breast cancer: These findings were further substantiated in therapy-resistant basal breast cancer cells and animal models, wherein the inhibition of the PERK–NRF2 axis reverted the MDR phenotype and sensitized the drug-resistant cancer cells to chemotherapy, decreasing their intracellular GSH content.